Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897536 | 0.82 | CYP19A1 (0.38) | CYP19A1TDP1HRH3 | |
| SCHEMBL1968523 | 0.80 | CYP19A1 (0.37) | CYP19A1CYP3A4HRH3 | |
| SCHEMBL10600899 | 0.77 | CYP2D6 (0.38) | CYP19A1CYP2D6ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL10424811 | 0.73 | CYP19A1 (0.48) | CYP19A1 | |
| SCHEMBL28080504 | 0.73 | MEN1 (0.45) | SIGMAR1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL6204930 | 0.72 | SIGMAR1 (0.35) | SIGMAR1CYP3A4CYP2D6ALDH1A1MEN1 | |
| Piperazine SCHEMBL28202645 | 0.72 | MEN1 (0.43) | SIGMAR1ALDH1A1PDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL12469489 | 0.70 | CYP2D6 (0.34) | CYP19A1SIGMAR1CYP2D6ALDH1A1MEN1 | |
| SCHEMBL3239300 | 0.70 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL2296855 | 0.69 | CYP19A1 (0.35) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1495022-B1 | DIAZABICYCLO ALKANE DERIVATIVES WITH NK1 ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2009-07-08 | — | — | EP | disclosed |
| US-20070082905-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-TRIAZOLYMETHYL-PIPERAZINE COMPOUNDS AND METHODS OF USING SAME | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082905-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-TRIAZOLYMETHYL-PIPERAZINE COMPOUNDS AND METHODS OF USING SAME | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| CN-1167698-C | New N-triazolyl methyl piperazine derivate using as neurokinin receptor antagonistic agent | ������ҩ������˾ | 2004-09-22 | — | — | CN | disclosed |
| EP-1176144-B1 | N-triazolylmethyl-piperazine derivatives as neurokinine receptor-antagonists | SOLVAY PHARM GMBH (DE) | 2003-07-09 | — | — | EP | disclosed |
| US-6407106-B1 | FOR THERAPY OF INFLAMMATORY DISTURBANCES OF THE GASTROINTESTINAL TRACT | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-06-18 | — | — | US | disclosed |
| US-6407106-B1 | FOR THERAPY OF INFLAMMATORY DISTURBANCES OF THE GASTROINTESTINAL TRACT | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-06-18 | — | — | US | disclosed |
| US-6407106-B1 | FOR THERAPY OF INFLAMMATORY DISTURBANCES OF THE GASTROINTESTINAL TRACT | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-06-18 | — | — | US | disclosed |
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-05-30 | — | — | US | disclosed |
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-05-30 | — | — | US | disclosed |
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-05-30 | — | — | US | disclosed |
| JP-2002053577-A | NEW N-TRIAZOLYLMETHYLPIPERAZINE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, INTERMEDIATE PRODUCT AND MEDICINE CONTAINING THE DERIVATIVE | SOLVAY PHARMACEUT GMBH | 2002-02-19 | — | — | JP | disclosed |
| CN-1335316-A | New N-triazolyl methyl piperazine derivate using as neurokinin receptor antagonistic agent | SOLVAY PHARM GMBH (DE) | 2002-02-13 | — | — | CN | disclosed |
| EP-1176144-A1 | N-triazolylmethyl-piperazine derivatives as neurokinine receptor-antagonists | Solvay Pharmaceuticals GmbH (DE) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | NPSR1, NTSR2, NTSR1 | CYP19A1 1801/4885SIGMAR1 134/4885CYP3A4 3303/4885 |
| US-20070082905-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-TRIAZOLYMETHYL-PIPERAZINE COMPOUNDS AND METHODS OF USING SAME | NT5C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PNLIP | CYP19A1 1728/4885SIGMAR1 2492/4885CYP3A4 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.